These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 2661434

  • 1. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans.
    Delabays A, Nussberger J, Porchet M, Waeber B, Hoyos P, Boger R, Glassman H, Kleinert HD, Luther R, Brunner HR.
    Hypertension; 1989 Jun; 13(6 Pt 2):941-7. PubMed ID: 2661434
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
    Gupta SK, Granneman GR, Boger RS, Hollenberg NK, Luther RR.
    Drug Metab Dispos; 1992 Jun; 20(6):821-5. PubMed ID: 1362933
    [Abstract] [Full Text] [Related]

  • 3. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.
    Cordero P, Fisher ND, Moore TJ, Gleason R, Williams GH, Hollenberg NK.
    Hypertension; 1991 Apr; 17(4):510-6. PubMed ID: 2013477
    [Abstract] [Full Text] [Related]

  • 4. Hemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers.
    Nussberger J, Delabays A, De Gasparo M, Cumin F, Waeber B, Brunner HR, Ménard J.
    Hypertension; 1989 Jun; 13(6 Pt 2):948-53. PubMed ID: 2661435
    [Abstract] [Full Text] [Related]

  • 5. Comparative effects of three different potent renin inhibitors in primates.
    Clozel JP, Fischli W.
    Hypertension; 1993 Jul; 22(1):9-17. PubMed ID: 8319997
    [Abstract] [Full Text] [Related]

  • 6. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
    Fisher ND, Allan DR, Gaboury CL, Hollenberg NK.
    Hypertension; 1995 May; 25(5):935-9. PubMed ID: 7737730
    [Abstract] [Full Text] [Related]

  • 7. Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria.
    Jackson B, Liu G, Perich RB, Paxton D, McNicols L, Gutteridge G, Johnston CI.
    Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):163-6. PubMed ID: 8039272
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
    Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR.
    J Cardiovasc Pharmacol; 1990 Feb; 16 Suppl 4():S76-81. PubMed ID: 1705633
    [Abstract] [Full Text] [Related]

  • 9. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.
    Neutel JM, Luther RR, Boger RS, Weber MA.
    Am Heart J; 1991 Oct; 122(4 Pt 1):1094-100. PubMed ID: 1656720
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
    Gupta SK, Granneman GR, Packer M, Boger RS.
    J Cardiovasc Pharmacol; 1993 May; 21(5):834-40. PubMed ID: 7685457
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J, Wuerzner G, Jensen C, Brunner HR.
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
    Fisher ND, Allan D, Kifor I, Gaboury CL, Williams GH, Moore TJ, Hollenberg NK.
    Hypertension; 1994 Jan; 23(1):44-51. PubMed ID: 8282330
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of chronic infusion of renin inhibitor A-64662 in sodium-depleted monkeys.
    Verburg KM, Kleinert HD, Kadam JR, Chekal MA, Mento PF, Wilkes BM.
    Hypertension; 1989 Mar; 13(3):262-72. PubMed ID: 2646217
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hemodynamics, biochemical effects, and pharmacokinetics of the renin inhibitor remikiren in healthy human subjects.
    Kleinbloesem CH, Weber C, Fahrner E, Dellenbach M, Welker H, Schröter V, Belz GG.
    Clin Pharmacol Ther; 1993 May; 53(5):585-92. PubMed ID: 8491068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.